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Today, shock wave lithotripsy (SWL), percutaneous nephrolithotomy (PCNL), and flexible ureterorenoscopy (URS) are the most
widely used modalities for the management of renal stones. In earlier series, treatment success of renal calculi assessed with KUB
radiography, ultrasound, or intravenous pyelography which are less sensitive than CT that leads to be diversity of study results in
reporting outcome. Residual fragments (RFs) after interventional therapies may cause pain, infection, or obstruction. The size and
location of RFs following SWL and PCNL are the major predictors for clinical significant symptoms and stone events requiring
intervention. There is no consensus regarding schedule for followup of SWL, PCNL, and flexible URS. Active monitoring can be
recommended when the stones become symptomatic, increase in size, or need intervention. RFs <4 mm after SWL and<2 mm after
PCNL and flexible URS could be actively monitored on an annual basis with CT. Early repeat SWL and second-look endoscopy are
recommended after primary SWL and PCNL, respectively. There is insufficient data for flexible URS, but RFs can be easily treated
with repeat URS. Finally, medical therapy should be tailored based on the stone analysis and metabolic workup that may be helpful
to prevent regrowth of the RFs.
1. Introduction
Urolithiasis is a common disorder, affecting 3% to 5% of the
population in industrialized countries and gradually increas-
ing all around the world [1, 2]. Today, shock wave lithotripsy
(SWL), percutaneous nephrolithotomy (PCNL), and flexible
ureteroscopy (URS) are widely used for renal stones. The
overall success rates of SWL, PCNL, and URS in renal stones
are 13.6–91.2% [3–5], 40–90% [6], and 34–92.2% [7, 8] in
different studies, respectively. The success of these treatments
also accepted free-of-stone rates in a radiologic studies such
as kidney ureter bladder (KUB) radiography, ultrasonogra-
phy (US), and abdominal computerized tomography (CT).
CT is certainly the most sensitive method for assessing
residual stones. Although CT detects stone fragments down
to 1 mm in all subtypes of stones (radiolucent uric acid
or cystine calculi as well as calcium-containing stones), the
clinical value of being able to detect very small fragments
remains debatable [9]. Besides, detecting negligible RF with
CT is time-consuming and expensive. Although the renal
stone protocol on newer multidetector scanners has been
widely used, they lead to expose 25–50-fold higher doses
of radiation than KUB radiography [10]. The advantages
of ultrasound are providing comparable precision and
detecting stones down to a diameter of 2 mm [11]. The
clinicians suggested that evaluation of asymptomatic patients
after SWL could be limited to routine radiologic studies such
as KUB radiography and US [11–14].
Clinically insignificant residual stone fragments (CIRF)
defined as residual calculi <4 or 5 mm while the patient
is asymptomatic and the stone composition is not struvite
or infection stone [15–17]. Residual fragments (RF) may
cause pain, infection, or obstruction whether clinically
significant or not. These patients could need auxiliary
measures, including further SWL sessions, double-J stent
insertions, or endoscopic surgical treatment. In addition, RFs
are important that may act as nidus for regrowth. At this
point of view, term of CIRF reflects a common and still
controversial problem for SWL, PCNL, or URS.
To define follow-up protocols and timing of auxiliary
intervention, better understanding of the natural history
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of RFs following endourological treatments in renal stones
should be needed. In this paper, we discussed fate of RF
following SWL, PCNL, and flexible URS in kidney stones
with recent literature.
2. Residual Fragments following SWL
In recent literature, several studies evaluated the fate of
RFs after SWL [11–14, 18]. Spontaneous stone passage was
found in 13.6% to 51.3% of the patients with mean followup
between 15 and 57 months. Stone size remained stable in
17.3% to 52.6% of the patients, while stone regrowth was
encountered in 21.4% to 69%. El-Nahas et al. reported that
52 (33.7%) of 154 patients had significant clinical stone
event that need further intervention (mostly SWL) [18].
Osman et al. noted that 21.4% of the residual stone led
to stone recurrence and need for retreatment [14]. The
spontaneous clearance rate was affected by location of RF.
The highest rates are seen in the ureter. In addition, many
investigators emphasized that RFs are commonly localized to
lower-pole calyces after SWL wherever treated in the kidney
[5]. In a review, the authors concluded that 25% of the
patients with CIRF will become stone-free, 50% will remain
symptom-free, 20% will experience a clinically significant
stone episode, and 4% to 25% of patients will need a
secondary intervention, especially SWL [16]. According to
this prediction, auxiliary endoscopic intervention should be
considered as overtreatment in asymptomatic patients [16].
In a recent systematic review, the natural history and clinical
significance of small and asymptomatic RFs after SWL were
extensively discussed with data of four studies. Totally 463
patients with CIRF (<5 mm in diameter) were followed with
a period of 15 months to 4.9 years. The stone-free rates
were 23.8% to 78.9% and 10.7% to 41.9% of the stones
remained stable. The stone size increased in 2% to 58.6% of
the patients. Between 41.4% and 100% of the patients were
asymptomatic while up to 58.6% had a symptomatic episode
or needed intervention with a mean followup at 15 to 57
months after SWL [19].
Most investigators indicated that the risk factors of CIRF
becoming clinically significant are stone burden and number
and location of RF [14, 18]. The rate of complications and
number of auxiliary interventions increased during long
follow-up period [11]. El-Nahas et al. noted that patients
with previous stone disease had 4.26 times higher incidence
for stone events [18]. In a prospective study, the authors
could not find any relationship between metaphylaxis and
stone regrowth [14]. The results of these studies reflect
that significant numbers of patients will need auxiliary
intervention or be symptomatic during followup of SWL
treatment. Consequently, the patients with RF should be
actively monitored whether clinically significant or not.
On the other hand, in a prospective randomized com-
parative study, the author suggested that SWL retreatment
promotes discharge of persistent caliceal RF after primary
SWL [20]. However, it is taking into consideration the
potentially higher side effects and additional cost against the
advantages of a higher stone-free rate by SWL retreatment.
As a conclusion, there is no consensus regarding schedule
for followup. Active monitoring can be recommended when
the stones become symptomatic, increase in size, or need
intervention. Most studies reported that the clearance rate
is higher at 6 months, but spontaneous clearance may last
up to 24 months [11, 16, 18]. In standard followup, the
authors recommended clinical examination, urine culture,
and routine radiographic studies as KUB radiography and/or
renal US at 3-, 6-, or 12-month intervals. Such an intense
followup may not be indicated for all patients because
spontaneous stone clearance asymptomatically occurs in
most of the patients. Therefore, any auxiliary procedures are
rarely required. We recommend the initial followup can be
performed at 6 months and it can be followed by an annual
schedule for the patients who were not clear at that time. The
intervention should be relatively noninvasive and consisted
of either repeated SWL or retrograde endoscopy.
3. Residual Fragments following PCNL
Percutaneous nephrolithotomy is an effective minimally
invasive procedure that is preformed for treatment of large
and complex calculi [21]. Altunrende et al. investigated
the medium-term outcome of CIRFs. They also measured
24-hour urine metabolic analysis. After PCNL, 38 patients
with CIRFs followed periodically in a median time of 28.4
months. Ten (26.3%) patients had symptomatic episode that
need medical therapy. The RF size was stable or decreased
in 27 (71.1%) cases whilst increased in 8 (21.1%) patients.
Spontaneous stone rate was 7.9% in medium term of
followup. They concluded that the progression could be seen
in 2-year followup, whereas presence of risk factors on 24-
hour urine metabolic analysis could not predict growth of
RFs [22]. Ganpule and Desai retrospectively examined in 187
patients to evaluate the fate of residual stones after PCNL
[23]. 57.7% of RF was located in the lower calix, and the
mean size of RF was 38.6 ± 52 mm2. Fourty-five percent
of the patients were stone-free without intervention at a
mean followup of 24 months. Most of the stones (65.47%)
spontaneously passed in 3 months. Small RFs (<25 mm2) in
renal pelvis had best clearance rate. In addition, a history of
previous intervention, renal failure, metabolic abnormalities
such as hyperuraecemia and hypercalciuria, size of RF, and
experience of surgeon affected the fate of RF after PCNL in
multivariate analysis. Raman et al. prospectively evaluated
42 patients with RF after PCNL with a median followup
of 41 months [24]. They performed abdominal CT to
determine the RF and classify the RF by using cut-off size
as 2 mm. Sixty percent of RF was 2 mm or smaller and
79% was <5 mm. The location of RF was 47% lower, 32%
middle, 24% upper pole, and 18% renal pelvis/ureter. Forty-
three percent of patients experienced a stone-related event
with a median time to occurrence at 32 months. Of these
patients, 61% underwent auxiliary procedures such as URS,
PCNL, SWL, nephrectomy, and double-J stent placement,
but mostly URS. They calculated the estimated 3- and 5-
year event-free probabilities were 74% and 48%, respectively.
On multivariate analysis, a maximum RF size >2 mm and
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location in the renal pelvis or ureter independently predicted
a stone-related event. The probability of needing a second
surgical procedure correlated with RF size. Eight percent of
patients with RFs <2 mm underwent surgical retreatment
compared with 53% of patients with RFs >2 mm. These
results indicate that patients with RFs >2 mm or fragments
located in the renal pelvis or ureter should be treated
immediately. On the other hand, some authors evaluated cost
comparison of immediate second-look endoscopy against
surveillance in post-PCNL RFs. They concluded that second-
look endoscopy is cost advantageous in the patients with RF
>4 mm following PCNL which generally leads to stone event
[25].
The schedule of followup following PCNL is still con-
troversial. Taking into consideration that the majority of
these stones will pass spontaneously without causing any
symptoms during the first year of followup, an annual
followup with a CT scan could be sufficient [19].
4. Residual Fragments following Flexible URS
Owing to technological advances, flexible URS has expanded
its indications to include the stones in kidney [26]. The
indication of flexible URS for renal stones is the stones less
than 15 mm which do not respond to SWL [27]. The one of
the advantages of flexible URS is the possibility of treating
renal and ureteral stones in the same patient in a single
session. In early series, treatment success of renal calculi
was assessed with KUB radiography, US, or intravenous
pyelography which are less sensitive than CT that leads to be
diversity of study results. Breda et al. evaluated 51 patients
with 161 renal stones (mean stone size of 6.6 mm) and they
found the overall stone-free rate after single and second
procedures was 64.7% and 92.2%, respectively [8]. In a
different study, Perlmutter et al. evaluated the impact of stone
location on success rates of flexible URS [28]. A total of 86
renal stones were treated, and the stone-free rates for upper-,
middle-, and lower-caliceal stones were 100%, 95.8%, and
90.9%, respectively. They concluded that stone location does
not significantly affect stone clearance rates. In a prospective
randomized trial, Pearle et al. compared SWL (32 patients)
and URS (35 patients) for lower-pole caliceal stones of 1 cm
or less [29]. The stone-free rates of SWL and flexible URS
were 35% and 50%, respectively. They concluded that there
was a statistically insignificant difference in stone-free rates
between SWL and URS for the treatment of small lower-
pole renal calculi. However, SWL was associated with greater
patient acceptance and shorter convalescence. Tanriverdi et
al. evaluated the stone-free rate of flexible URS in renal
calculi by classifying the RFs as the largest single fragment
<2 mm, <4 mm, and >4 mm in CT [30]. The success rates
were 50.4%, 62.8%, and 84.1% in stone-free, CIRF <2 mm
and CIRF <4 mm, respectively.
According to aforementioned studies, all RFs may be
regrowth and become symptomatic regardless of stone size
[13, 24, 30]. In a recent study, Rebuck et al. evaluated the
fate of RFs following flexible URS in 51 patients with renal
calculi [31]. Although the follow-up protocol was complex,
patients with RFs actively monitored with abdominal CT and
term of CIRF (≤4 mm) was used for RFs. They excluded
patients who had fragments in ureter after URS and patients
with complex renal anatomy. Mean follow-up duration
was 18.9 months. During the follow-up period, 19.6% of
the patients experienced at least one stone event, 21.7%
spontaneously passed their fragments, and 58.7% remained
asymptomatic over time. The stone event occurs in mean
followup of 26.8 months. Most of the patients with stone
event treated with repeated URS. Among the patients with
spontaneous passage, 60% passed their fragments after a
mean followup of 9.1 months. In contrast to several studies,
stone regrowth rate was very low in this study. In addition,
the authors noted that stone events occur rather than lower-
pole RF location while most of remaining stones located in
lower pole. They attributed these results to small sample
size, compliance of their patients against stone prevention
therapy, and short followup of patients with asymptomatic
RFs. As a conclusion, approximately one in five patients will
experience stone events over 1.6 years after flexible URS and
most of them can easily be treated with URS. Although, there
is no consensus on the schedule of followup, asymptomatic
patients with RF can actively monitor with abdominal CT
until patients become symptomatic or 2 years of followup.
5. Medical Management on RF following
Endourological Procedures
Several authors discussed medical therapy in the manage-
ment of RFs after SWL or PCNL [32–36]. Fine et al. evaluated
80 patients to determine the effect of medical therapy in a
retrospective study. Patients who received medical therapy
had significant decrease in the stone-formation rate from a
median of 1.17 to 0.00 stones per patient per year while the
patients who did not receive medical therapy had a minimal
decrease from a median of 1.33 to 0.77 stones per patient
per year. The medically treated patients had a significantly
greater stone remission rate (63.9% versus 23.1%) and
lower stone burden increase (27.8% versus 61.6%) than the
untreated patients. Regarding patients with CIRF, 16% of
medically treated patients had fragment regrowth compared
with 54.5% of the untreated patients. The authors concluded
that medical therapy may alleviate stone regrowth in patients
with residual stone fragments after SWL [33]. Cicerello et al.
evaluated the effect of alkaline citrate therapy in patients
with RF <5 mm [32]. In up to 74% of calcium oxalate
patients and in up to 86% of infection stone patients, the RFs
became undetectable in 1 year of followup. The undetectable
RF rates of the patients were 32% and 40% in the control
group for calcium oxalate and infection stones, respectively.
RF regrowth rate decreased 47% to 5% in calcium oxalate
patients with medical treatment. No significant difference
was found for infection stones [32]. Similarly, Soygür et al.
reported that among the patients with lower-pole RFs after
SWL, the patients who were receiving citrate therapy showed
a significantly higher stone fragment-disappearance rate
(45.5% versus 12.5%) and less stone recurrence rate (56.6%
versus 87.5%) compared with the control group at 12 months
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of followup [36]. Kang et al. evaluated the effect of medical
therapy management in patients with RFs following PCNL.
Patients receiving medical therapy had a lower median stone-
free rate (0.02 versus 1.00 stones per patient per year) and
a higher remission rate (77% versus 21%) compared with
patients not receiving medical therapy. This result indicated
that medical therapy can inhibit new stone formation or
growth in patients with residual fragments after PCNL [34].
Afterwards, there is little evidence related to effectiveness
of medical therapy in patients with RFs after flexible URS.
Rebuck et al. speculated the high rate of stones remaining
stable was related to medical therapy strategy in particularly
lower-pole location [31].
There is no valuable data for determining the cost effec-
tiveness of medical therapy after interventional therapies.
However, the cost analysis of interventional therapies may
help to make better estimation for medical management.
Few studies have evaluated the cost of different treatment
strategies for treatment of renal calculi. Koo et al. compared
the cost effectiveness and outcome of SWL and flexible
URS for lower-pole renal calculi ≤20 mm [37]. The costs
of flexible URS and SWL for each session were calculated
approximately $4,116 and $673, respectively. In another
study, comparing clinical outcomes and the estimated cost
of PCNL and flexible URS for 2 to 3 cm renal stones,
the estimated cost of PCNL was significantly greater than
flexible URS ($19,845 versus $6,675, resp.) [38]. Regarding to
determine the cost effectiveness of medical therapy and pro-
phylaxis, Lotan et al. published an international comparison
for costs of medical treatments [39]. The authors classified
the treatments into 3 categories as conservative therapy
(comprised dietary modification without drug treatment or
metabolic evaluation), empiric medical therapy (both drug
and dietary treatment were initiated without metabolic eval-
uation in all patients), and directed medical therapy (based
on comprehensive metabolic evaluation). The study result
showed that conservative therapy was the least costly strategy
in all countries except the UK, but was associated with
the highest stone recurrence rate (0.3 stones/patient/year)
for recurrent stone formers. The empiric therapy amounted
$508 in America, $150 in Turkey, and $29 in UK per
patient in one year. In other countries with relatively low-
medication costs, only small differences between empiric
and conservative therapy were demonstrated. Drug therapy
(empiric and directed) was associated with a significantly
lower rate of stone recurrence than conservative therapy.
The authors emphasized that empiric therapy was minimally
more effective than directed therapy because of effectiveness
of medication in all treated patients whether they had a
metabolic abnormality or not. Thus, medical treatment
after interventional therapy seems to be more cost effective
than auxiliary treatments for RFs. As a conclusion, medical
therapy after endourological treatment should not replace
the appropriate interventional therapy that the best chance
to achieve a stone-free status with minimal morbidity. How-
ever, metabolic workup should immediately be performed
before stone therapy. It may help to diagnose underlying
metabolic abnormality and medical therapy may be begun
promptly.
6. Summary
The size and location of RFs following SWL and PCNL
therapies are the major predictors for clinical significant
symptoms and stone events which requiring intervention.
RFs <4 mm after SWL and <2 mm after PCNL and flexible
URS could be actively monitored on an annual basis with
CT. Early repeat SWL and second-look endoscopy are
recommended after primary SWL and PCNL, respectively.
There is no sufficient data for flexible URS but RFs can
be easily treated with repeat URS. Finally, medical therapy
according stone analysis and metabolic workup might be
helpful to prevent regrowth of the RFs.
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